All News
Filter News
Found 127 articles
-
Following a banner year marked by the approval and launch of its diabetes drug Mounjaro, Eli Lilly revealed at the 41st J.P. Morgan Healthcare Conference that it was preparing for another big year.
-
Lilly Announces 2023 Financial Guidance, Plans to Launch up to Four New Medicines
12/13/2022
Lilly expects to deliver strong financial and operational performance in 2023, highlighted by volume-driven revenue growth; potential launches for donanemab, mirikizumab, lebrikizumab and pirtobrutinib; potential regulatory submissions for tirzepatide in obesity; and numerous other anticipated pipeline advancements.
-
Almirall’s Nine-month 2022 Results
11/10/2022
Almirall, S.A., the global biopharmaceutical company based in Barcelona, has announced its 9M 2022 financial results.
-
Lilly Reports Solid Third-Quarter 2022 Financial Results and Continued Pipeline Progress
11/1/2022
Eli Lilly and Company announced its financial results for the third quarter of 2022.
-
Evommune’s Human Tissue-based Approach Enables Discovery and Development of Safer, Innovative Chr...
10/12/2022
Evommune’s novel human tissue-based assay system is proving to be a key differentiator as the company develops therapies to control chronic inflammation in autoimmune diseases. -
Lebrikizumab Dosed Every Four Weeks Maintained Durable Skin Clearance in Lilly's Phase 3 Monotherapy Atopic Dermatitis Trials
9/8/2022
New detailed results from Eli Lilly and Company's (NYSE: LLY) Phase 3 monotherapy studies in atopic dermatitis (AD) showed investigational lebrikizumab provided robust and durable improvements in skin clearance and itch for patients who achieved a clinical response* at Week 16 through one year of treatment.
-
Lilly Reports Second-Quarter Financial Results, Highlights Momentum of New Medicines and Pipeline Advancements
8/4/2022
Eli Lilly and Company announced its financial results for the second quarter of 2022.
-
Sanofi released its second quarter financial report just two days after it announced its new diversity initiative with HBCU Howard University. Plus: Up-and-coming eczema biologics to shake Dupixent's foothold
-
Almirall achieves Core Net Sales growth of 5.1% to 436.6 MM Euros in H1
7/25/2022
Almirall, S.A., the global biopharmaceutical company based in Barcelona, announced its H1 2022 financial results.
-
The Phase III ADvocate 1 and 2 studies on lebrikizumab showed that eight out of 10 patients with atopic dermatitis maintained skin clearance in the 12 months they had been under treatment.
-
Eight out of Ten Patients Maintained Skin Clearance at One Year in Lilly's Lebrikizumab Atopic Dermatitis Monotherapy Trials
6/7/2022
Eli Lilly and Company announced topline results from one-year analyses of the efficacy and safety of lebrikizumab, the company's investigational IL-13 inhibitor for the treatment of patients with moderate-to-severe atopic dermatitis.
-
Almirall delivers good business performance in Q1 and reiterates full year 2022 guidance
5/9/2022
Almirall, S.A., the global biopharmaceutical company based in Barcelona, has announced its Q1 2022 financial results.
-
Solid First-Quarter Financial Results Reflect Lilly's Continued Momentum into 2022
4/28/2022
Eli Lilly and Company announced its financial results for the first quarter of 2022.
-
ASLAN Pharmaceuticals Reports First Quarter 2022 Financial Results and Provides Corporate Update
4/27/2022
ASLAN Pharmaceuticals (Nasdaq: ASLN), a clinical-stage, immunology-focused biopharmaceutical company developing innovative treatments to transform the lives of patients, today announced financial results for the first quarter ended March 31, 2022, and provided an update on recent corporate activities.
-
It was a very busy week for clinical trial news, with much of it coming out of the American Association of Cancer Research Annual Meeting. Read on for details.
-
Eli Lilly has shared positive results of lebrikizumab combination therapy with topical corticosteroids, which is intended to treat atopic dermatitis (AD).
-
Lilly's Lebrikizumab Combined with Topical Corticosteroids Showed Significant Improvements in Disease Severity for Atopic Dermatitis
4/11/2022
At 16 weeks, 70 percent of patients with moderate-to-severe atopic dermatitis (AD) receiving lebrikizumab combined with standard-of-care topical corticosteroids (TCS) achieved at least 75 percent improvement in overall disease severity (EASI-75*) in the ADhere trial, Eli Lilly and Company (NYSE: LLY) announced today at the 4th Annual Revolutionizing Atopic Dermatitis (RAD) Conference.
-
The 2022 American Academy of Dermatology Annual Meeting saw several milestones for treatment explorations for inflammatory diseases. Here is some of the major news:
-
ASLAN Pharmaceuticals Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Corporate Update
3/25/2022
ASLAN Pharmaceuticals announced financial results for the fourth quarter and full year ended December 31, 2021, and provided an update on recent corporate activities.
-
ASLAN Pharmaceuticals Appoints Dermatology Veteran Dr Alex Kaoukhov as Chief Medical Officer
3/15/2022
ASLAN Pharmaceuticals announced the appointment of Alex Kaoukhov, MD, as Chief Medical Officer based in ASLAN’s US office, effective immediately.